Key points are not available for this paper at this time.
Thymidine kinase 2 deficiency (TK2d) is a rare autosomal recessive disorder that stems from a perturbation of the mitochondrial DNA maintenance. Nucleoside treatment has recently shown promise as a disease-modifying therapy. TK2d was initially associated with rapidly progressive fatal myopathy in children featuring mitochondrial DNA depletion. Subsequently, less severe variants of the disease were described, with onset of symptoms during adolescence or adulthood and associated with the presence of multiple mtDNA deletions. These less severe phenotypes have been reported in only 15% of the approximately 120 patients described worldwide. However, some reports suggest that these juvenile and adult-onset presentations may be more common. The objective of this study was to describe the clinical phenotype in a sample of patients from Spain.
Building similarity graph...
Analyzing shared references across papers
Loading...
Francisco C. Ceballos
University of Zurich
Pablo Serrano‐Lorenzo
Instituto de Salud Carlos III
Laura Bermejo‐Guerrero
Research Institute Hospital 12 de Octubre
Neurology Genetics
Building similarity graph...
Analyzing shared references across papers
Loading...
Ceballos et al. (Mon,) studied this question.
synapsesocial.com/papers/68e72652b6db6435876a0507 — DOI: https://doi.org/10.1212/nxg.0000000000200138
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: